Center for Lymphoid Malignancies

The Center for Lymphoid Malignancies at the Columbia University Medical Center is focused on the care of patients with lymphoid cancers, including patients with all forms of non-Hodgkin’s lymphoma (NHL; including for example peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL)), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and Hodgkin’s Disease. The Center offers a truly multidisciplinary approach to the care of our patients. At the core of the Centers’ activities is an emphasis on translating the latest scientific discoveries and developments into the most promising and innovative treatments for patients suffering from these diverse and complex diseases. This emphasis on translational medicine has allowed our physicians to pioneer several new treatments for patients with lymphoma. The Center houses one of the largest portfolio’s of clinical trials in the nation for patients with all forms of lymphoma and lymphoid leukemia. A highly coordinated multidisciplinary approach involving experts in bone marrow transplantation, early phase drug development and pharmacology, radiation oncology, radiology and hematopathology work collaboratively to offer not just the highest caliber care for patients, but to develop novel concepts that will change how we approach and manage these diseases in the future.

Presently, investigators in the Center are focused on a number of important translational areas in lymphoma research, including: (1) the development of epigenetic based treatment platforms for patients with CTCL and PTCL; (2) the laboratory and clinical development of novel small molecule inhibitors of NF-kB; (3) the discovery and validation of imaging biomarkers of response using magnetic resonance spectroscopy (MRS); (4) the clinical development of next generation monoclonal antibodies and antibody drug conjugates; and (4) the development of pharmacologic strategies to modulate important oncogenes like Bcl-6 in patients with DLBCL. In each of these cases, there is a strong emphasis on the translational development of these concepts from the laboratory to clinical care in a portfolio of nearly 20 clinical trials.


  • Owen A. O’Connor, M.D., Ph.D.
    Director for the Center for Lymphoid Malignancies
    Professor of Medicine and Experimental Therapeutics
    Co-Director, Program for Lymphoid Development & Malignancies
    Herbert Irving Comprehensive Cancer Center
  • George Deng, M.D., Ph.D.
    Assistant Professor of Medicine
  • Jennifer Amengual, M.D.
    Assistant Professor of Medicine
  • Ahmed Sawas, M.D.
    Instructor in Clinical Medicine


  • Victoria Serrano, Administrative Director
  • Ellen Neylon, N.P., Research and Practice Nurse
  • Sean Clark-Garvey, Research Study Coordinator
  • Ameet Narwal, Research Study Coordinator
  • Molly Patterson, Research Study Coordinator
  • Danielle Wright, Research Study Coordinator
  • Renee Lichtenstein, Patient Secretary
  • Tabitha Pitre, Patient Secretary


New Patient Appointments & Physician Referral
(212) 326-5720
NewYork-Presbyterian Operator
(212) 305-2500